Dianthus Therapeutics (NASDAQ: DNTH) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.85) by 3.53 percent. This is a 51.85 percent decrease over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $1.16 million which beat the analyst consensus estimate of $804.30 thousand by 44.60 percent. This is a 33.07 percent increase over sales of $874.00 thousand the same period last year.